Yona Bismuth-Evenzal1, Yehudit Gonopolsky2, David Gurwitz3, Iulian Iancu2, Abraham Weizman4, Moshe Rehavi5. 1. Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv 69978, Israel. 2. Beer Yaakov-Ness Ziona Mental Health Center, Beer Yaakov, Tel Aviv University, Tel Aviv 69978, Israel. 3. Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv 69978, Israel. 4. Geha Psychiatric Hospital and Felsenstein Medical Research Center, Beilinson Campus, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. 5. Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv 69978, Israel. Electronic address: mrehavi@post.tau.ac.il.
Abstract
BACKGROUND: Chronic treatment with selective serotonin reuptake inhibitors (SSRIs) reduces the risk and severity of cardiovascular diseases. SSRIs block the serotonin transporter, thereby inhibiting serotonin (5-HT) uptake into presynaptic neurons as well as into platelets where 5-HT is stored in dense granules. When 5-HT is released in response to agonists it enhances platelet aggregation induced by injury-related signals. Chronic administration of SSRIs may thus reduce platelet aggregability secondary to depletion of platelets' serotonin stores. METHODS: The study included ten DSM-IV-TR major depression (MDD) and four obsessive compulsive disorder (OCD) patients and fourteen healthy untreated age- and sex-matched controls. The patients were chronically medicated (6-108 months) with various SSRIs. Platelet serotonin content was assessed in fresh samples of platelet rich plasma (PRP) using radioimmunoassay. ADP, collagen, arachidonic acid and epinephrine were used as inducers of platelet aggregation measured in PRP by turbometric method in a microplate reader. RESULTS: Lower platelet serotonin content (66%; p<0.05) and lower ADP, collagen or epinephrine-induced platelet aggregation (10-52%; p<0.05) were detected in PRP of SSRI-medicated patients, while no such effect was obtained with arachidonic acid. LIMITATIONS: The small sample size and the co-treatment with non-SSRI drugs such as benzodiazepines. CONCLUSION: Patients chronically medicated with SSRIs exhibit lower platelet 5-HT content and reduced platelet aggregation induced by ADP, collagen and epinephrine, but not by arachidonic acid. Our observations may explain the increased bleeding risk associated with chronic SSRI treatment as well as the reported beneficial effect of SSRIs in prevention of recurrent myocardial infarction.
BACKGROUND: Chronic treatment with selective serotonin reuptake inhibitors (SSRIs) reduces the risk and severity of cardiovascular diseases. SSRIs block the serotonin transporter, thereby inhibiting serotonin (5-HT) uptake into presynaptic neurons as well as into platelets where 5-HT is stored in dense granules. When 5-HT is released in response to agonists it enhances platelet aggregation induced by injury-related signals. Chronic administration of SSRIs may thus reduce platelet aggregability secondary to depletion of platelets' serotonin stores. METHODS: The study included ten DSM-IV-TR major depression (MDD) and four obsessive compulsive disorder (OCD) patients and fourteen healthy untreated age- and sex-matched controls. The patients were chronically medicated (6-108 months) with various SSRIs. Platelet serotonin content was assessed in fresh samples of platelet rich plasma (PRP) using radioimmunoassay. ADP, collagen, arachidonic acid and epinephrine were used as inducers of platelet aggregation measured in PRP by turbometric method in a microplate reader. RESULTS: Lower platelet serotonin content (66%; p<0.05) and lower ADP, collagen or epinephrine-induced platelet aggregation (10-52%; p<0.05) were detected in PRP of SSRI-medicated patients, while no such effect was obtained with arachidonic acid. LIMITATIONS: The small sample size and the co-treatment with non-SSRI drugs such as benzodiazepines. CONCLUSION:Patients chronically medicated with SSRIs exhibit lower platelet 5-HT content and reduced platelet aggregation induced by ADP, collagen and epinephrine, but not by arachidonic acid. Our observations may explain the increased bleeding risk associated with chronic SSRI treatment as well as the reported beneficial effect of SSRIs in prevention of recurrent myocardial infarction.
Authors: Tam Truong Donnelly; Jassim Mohd Al Suwaidi; Awad Al-Qahtani; Nidal Asaad; Najlaa Abdul Qader; Rajvir Singh; Tak Shing Fung; Irem Mueed; Shima Sharara; Noha El Banna; Sarah Omar Journal: J Immigr Minor Health Date: 2015-08
Authors: Marc G Berman; Ethan Kross; Katherine M Krpan; Mary K Askren; Aleah Burson; Patricia J Deldin; Stephen Kaplan; Lindsey Sherdell; Ian H Gotlib; John Jonides Journal: J Affect Disord Date: 2012-03-31 Impact factor: 4.839
Authors: Eriton E L Valente; James L Klotz; Gyuchul Ahn; Kyle R McLeod; Hannah M Herzing; Mindy King; David L Harmon Journal: J Anim Sci Date: 2020-12-01 Impact factor: 3.159